Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus

被引:63
作者
Goldberg, Robert J. [1 ]
Urowitz, Murray B. [1 ]
Ibanez, Dominique [1 ]
Nikpour, Mandana [1 ]
Gladman, Dafna D. [1 ]
机构
[1] Univ Toronto, Div Rheumatol, Toronto Western Hosp, Ctr Prognosis Studies Rheumat Dis,Lupus Clin, Toronto, ON M5T 2S8, Canada
关键词
SYSTEMIC LUPUS ERYTHEMATOSUS; CORONARY ARTERY DISEASE; WOMEN; RISK FACTORS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; HEART-DISEASE; ATHEROSCLEROSIS; COHORT; HYPERTRIGLYCERIDEMIA; PREVALENCE; NECROSIS; FEATURES; RATES;
D O I
10.3899/jrheum.090011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To ascertain coronary artery disease (CAD) outcomes and predictive factors in a prospective Study of patients with systemic lupus erythematosus (SLE) and matched healthy controls. Methods. SLE patients and non-SLE age-matched controls without a history of CAD were recruited into a prospective Study between 1997 and 1999. CAD events were assessed at clinic visit for SLE patients and through telephone interview and chart review for controls. All events were verified with patient medical records. Results. Followup information wits available on 237 controls and 241 SLE patients. The mean followup time was 7.2 years. Univariate analyses identified age and postmenopausal status as predictors of CAD in both the groups. Sedentary lifestyle, hypertension, the presence of metabolic syndrome, and the number of Framingham risk factors were predictive in the control group only. The 10-year risk of CAD score was predictive in both goups but was not as marked in the SLE group as in the controls. None of the lipid subfractions were predictive for CAD in the SLE group, whereas in the controls, a high triglyceride level >= 2.8 was predictive. Time-to-event multivariate analysis for CAD in all subjects revealed SLE itself, older age, and triglycerides >= 2.8 to be highly predictive for CAD. Conclusion. In a prospective study of patients with SLE and matched controls followed over a median of 8 years, patients with SLE developed significantly more CAD events than controls. Accounting for demographic variability, CAD risk factors, and lipid factors, SLE is an independent risk factor for the development of CAD. (First Release Oct 15 2009: J Rheumatol 200936:2454-61; doi: 10.3899/jrheum.090011)
引用
收藏
页码:2454 / 2461
页数:8
相关论文
共 36 条
[1]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]   Premature coronary-artery atherosclerosis in systemic lupus erythematosus [J].
Asanuma, Y ;
Oeser, A ;
Shintani, AK ;
Turner, E ;
Olsen, N ;
Fazio, S ;
Linton, MF ;
Raggi, P ;
Stein, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2407-2415
[3]   Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus [J].
Bessant, R ;
Hingorani, A ;
Patel, L ;
MacGregor, A ;
Isenberg, DA ;
Rahman, A .
RHEUMATOLOGY, 2004, 43 (07) :924-929
[4]   Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study [J].
Bessant, Rupa ;
Duncan, Rachel ;
Ambler, Gareth ;
Swanton, Jo ;
Isenberg, David A. ;
Gordon, Caroline ;
Rahman, Anisur .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (06) :892-899
[5]   Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies [J].
Borba, EF ;
Bonfa, E .
LUPUS, 1997, 6 (06) :533-539
[6]   Risk factors for coronary heart disease in women with systemic lupus erythematosus -: The Toronto Risk Factor Study [J].
Bruce, IN ;
Urowitz, MB ;
Gladman, DD ;
Ibañez, D ;
Steiner, G .
ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3159-3167
[7]   Systemic lupus erythematosus and "lupus dyslipoproteinemia" [J].
de Carvalho, Jozelio Freire ;
Bonfa, Eloisa ;
Borba, Eduardo Ferreira .
AUTOIMMUNITY REVIEWS, 2008, 7 (03) :246-250
[8]  
Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO
[9]  
2-I
[10]  
Gladman DD., 2000, J Rheumatol, V29, P288, DOI DOI 10.3899/JRHEUM.110550